Fuchs' Endothelial Dystrophy
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Oregon TherapeuticsFrance - Paris
1 programDSAEK with graft shaping and smoothingN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Trefoil TherapeuticsTTHX1114
Oregon TherapeuticsDSAEK with graft shaping and smoothing
Clinical Trials (2)
Total enrollment: 55 patients across 2 trials
TTHX1114(NM141) in Combination With DWEK/DSO
Start: Feb 2021Est. completion: Jan 202349 patients
Phase 2Completed
OCT-guided DSAEK Graft Shaping and Smoothing
Start: Jan 2012Est. completion: Aug 20146 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.